Organization (Industry)
MODERNA, INC.
ClinicalTrials.gov lists MODERNA, INC. as lead sponsor of 115 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 more sections with rows · 12 sections measured, none recorded
Logo Moderna, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers MODERNA, INC. and 1 company grouped under it: 115 lead-sponsored trials (0 its own, 115 in the grouped companies) and 4 legal-entity registrations (2 its own, 2 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| MODERNATX, INC. | 115 | 2 |
Disease areas (48)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| COVID-19 | 43 |
| Influenza, Human | 22 |
| Cytomegalovirus Infections | 9 |
| Recurrence | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
Showing 5 of 48 disease areas.
Trials by start year as sponsor or collaborator (1)
| Year | Trials started |
|---|---|
| 2023 | 1 |
No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
Journals published in (55)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 13 |
| The Journal of infectious diseases | 12 |
| Vaccine | 10 |
| Nature medicine | 8 |
| The Lancet. Infectious diseases | 7 |
Showing 5 of 55 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 268 | 119 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 1,944,000,000 | -2,822,000,000 | 3,132,000,000 |
| 2024 | 3,236,000,000 | -3,561,000,000 | 4,543,000,000 |
| 2023 | 6,848,000,000 | -4,714,000,000 | 4,845,000,000 |
| 2022 | 19,263,000,000 | 8,362,000,000 | 3,295,000,000 |
| 2021 | 18,471,000,000 | 12,202,000,000 | 1,991,000,000 |
| 2020 | 803,000,000 | -747,000,000 | 1,370,000,000 |
| 2019 | 60,000,000 | -514,000,000 | 496,000,000 |
| 2018 | 135,068,000 | -384,734,000 | 454,082,000 |
| 2017 | 205,825,000 | -255,916,000 | 410,459,000 |
| 2016 | 108,396,000 | -216,211,000 | 274,717,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (18)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-03-03 | Other financing | not disclosed | Sec extracted |
| 2026-03-03 | Other financing | not disclosed | Sec extracted |
| 2025-11-19 | Debt financing | 600,000,000 | Sec extracted |
| 2023-05-05 | Other financing | not disclosed | Edgar offerings |
| 2021-04-18 | Other financing | not disclosed | Sec extracted |
Showing 5 of 18 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | 49.0% | not disclosed |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Vertex, Inc. | Co sponsors trial with | 1 |
Latest dated events (432)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 432 events.
Biomarker capability evidence (2)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CFTR | Trial collaborator | Named in trial inclusion criteria |
| CFTR | Trial collaborator | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, approved assets, sponsor delivery record, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.